Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 207127 Formulations in Healthy Volunteers
NCT02182414Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2009
- Primary completion
- Sep 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of deleobuvir in hepatitis C (HCV) (8 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity up to 48 hours and Maximum measured concentration up to 48 hours. Started May 2009; status: completed.
02
Drugs
deleobuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182414.